

Docket No.: 30694/41506
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Orit Kollet et al.

Application No.: 10/552,299

Confirmation No.: 2069

Filed: August 25, 2006

Art Unit: 1636

For: Stem Cells Having Increased Sensitivity to SDF-1
and Methods of Generating and Using Same

Examiner: Shen, W.C.W.

RESPONSE TO SECOND RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed November 12, 2010, Applicants hereby provisionally elect the claims of Group IX, i.e., claims 1-7, and 9, in part, and 30-36, 38, and 39, for continued examination. In response to the Office's requirement for election of species, Applicants elect MMP-2. Claims 1-7, and 9, in part, and 30-36, 38, and 39 read on the elected species. Applicants respectfully traverse the requirement for restriction for the reasons set forth below.

The Restriction Requirement

In the Office Action, the Examiner revised the restriction requirement mailed on February 6, 2009. The Examiner rejoined the claims of Group I to the previously elected and examined Group IX, to the extent that CXCR4 is the chemoattractant receptor of hematopoietic stem cells. The Examiner stated that "Applicant is advised to respond to this office action accordingly for the clarity of record, and be consistent with Applicant's response filed on 03/06/2009." Applicants incorporate by reference the arguments found in the response filed March 6, 2009 used to traverse the restriction requirement.